



# CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.  
E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

To  
BSE Limited,  
P.J. Towers, Dalal Street, Fort,  
Mumbai - 400001

03.11.2021

Dear Sir/Madam,

**Sub:** Typographical error in the un-audited financials for the quarter ended 30/06/2021 uploaded on the BSE website on 13/08/2021.

**Ref:** Scrip code: 538965

.....

With reference to the subject cited, this is to inform the Exchange that the un-audited financial results for the quarter ended 30/06/2021 submitted to BSE on 13/08/2021 had a small typographical error at point no. XI of the financials. The figure of other equity for the quarter ended 30/06/2021 was taken as 68.77 lakhs (excluding the Reserves) and Quarter ended 31/03/2021 was taken as 1474.082 (Including Reserves) but the actual figure is 1,871.02 lakhs for 30/06/2021, 1802.249 for 31/03/2021 (including Reserves). There is no change in the other items of the financials.

We are now attaching herewith the revised copy of the financials for your kind perusal and request you to please replace this copy with the earlier one for the information of the shareholders.

Thanking you,

Yours faithfully,  
For Concord Drugs Limited

*S. Nagi Reddy*

S. Nagi Reddy  
Chairman & Managing Director  
DIN: 01764665





# CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com

Website : www.concorddrugs.in

## STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June 2021

[Rs. in Lakhs]

Particulars	Quarterly ended		Year ended	
	30-Jun-21 (UnAudited)	31-Mar-21 (Audited)	30-Jun-20 (UnAudited)	31-Mar-21 (Audited)
<b>I Revenue from Operations</b>				
a. Net sales from Operations	2,021.94	834.63	1,820.32	5,135.70
b. Other Operating Income	2.152	2.15	2.15	9.46
<b>II Other Income</b>				
<b>III Total Revenue (I+II)</b>	<b>2,024.10</b>	<b>836.78</b>	<b>1,822.48</b>	<b>5,145.16</b>
<b>IV Expenses</b>				
a. Cost of Material Consumed	1,566.49	552.78	1,497.57	4,049.15
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	18.48	42.56	96.72	168.67
c. Employees Benefit Expenses	104.88	92.29	87.00	375.55
d. Finance Costs	95.76	27.49	43.91	142.03
e. Depreciation and Amortisation expense	53.16	33.22	31.73	136.53
f. Other expenses	105.30	74.36	43.20	220.35
<b>Total Expenses</b>	<b>1,944.07</b>	<b>822.70</b>	<b>1,800.12</b>	<b>5,092.28</b>
<b>Profit/ (Loss) before Exceptional item and tax (III-IV)</b>	<b>80.03</b>	<b>14.09</b>	<b>22.35</b>	<b>52.88</b>
<b>V Exceptional Items</b>		<b>23.98</b>		<b>376.32</b>
<b>VI Profit/ (Loss) before tax (V-VI)</b>	<b>80.03</b>	<b>38.07</b>	<b>22.35</b>	<b>429.20</b>
<b>VII Tax Expense:</b>	<b>11.26</b>	<b>4.50</b>	<b>5.81</b>	<b>101.03</b>
<b>VIII a. Current tax</b>	24.682	0.16	5.46	47.07
b. Deferred tax charge/credit	-13.421	4.35	0.36	53.96
<b>IX Profit/ (Loss) for the period (VII-VIII)</b>	<b>68.77</b>	<b>33.567</b>	<b>16.54</b>	<b>328.17</b>
<b>X Other Comprehensive Income</b>	-	-	-	-
Items that will not be reclassified to profit or loss	-	-	-	-
<b>Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)</b>	<b>68.77</b>	<b>33.57</b>	<b>16.54</b>	<b>328.17</b>
<b>XI Paid-up equity share capital</b>	<b>874.38</b>	<b>874.38</b>	<b>874.38</b>	<b>874.38</b>
(Face value of the share- Rs. 10 each)				
<b>Other Equity</b>	<b>1,871.02</b>	<b>1,802.25</b>	<b>1,490.62</b>	<b>1,474.082</b>
<b>XII Earnings per share (of Rs. 10 each)</b>				
<b>XIII a. Basic (in Rs)</b>	0.79	0.38	0.19	3.75
b. Diluted (in Rs)	0.79	0.38	0.19	3.75

### Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 13th August, 2021
- The company adopted the Indian Accounting standards (Ind AS) from 01.04.2017 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.  
Note: The figures for the qtr ended March 31, 2021 are balancing figures between the Audited figures of the full financial year ended 31, March 2020 & the published year to date figures upto 9 months ended Dec 31, 2019
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company www.concorddrugs.in

Place: Hyderabad  
Date: August 13, 2021



By Order of the Board  
For Concord Drugs Limited  
S. N. R. M.  
Managing Director  
DIN: 01764665